The effect of DTC on humoral response restoration and thymocyte subpopulations in cyclophosphamide-immunosuppressed mice.

Immunopharmacol Immunotoxicol

Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Agricultural University, Wrocław, Poland.

Published: February 1994

The effects of sodium diethyldithiocarbamate (DTC) on humoral response to SRBC and restoration of the response impaired by a single cyclophosphamide dose (200 mg/kg) were tested on mice. Moreover, the effect of DTC (20 mg/kg) on thymocyte subpopulations was tested on non-immunized mice previously treated with cyclophosphamide. It was found that DTC (20 mg/kg) administered to the immunized mice enhanced humoral response to SRBC, which was reflected in the increased number of PFC and (7S) serum hemagglutinin titer. In contrast, partial restoration of the primary humoral response after DTC injection was observed in the mice administered a single cyclophosphamide dose. The effect of DTC was stronger after 6 days following cyclophosphamide injection, i.e. at the time when spontaneous restoration of T lymphocytes begins. In addition, it was found that DTC given to non-immunized mice treated with cyclophosphamide had a modulating effect on thymocyte subpopulations. Depending on the time of exposure to cyclophosphamide, DTC either increased the percentage of CD4 thymocytes or decreased the percentage of CD8, which subsequently led increased CD4/CD8 coefficient. DTC did not change the suppressing action of cyclophosphamide on the percentage of double-positive thymocytes.

Download full-text PDF

Source
http://dx.doi.org/10.3109/08923979409029903DOI Listing

Publication Analysis

Top Keywords

humoral response
16
thymocyte subpopulations
12
dtc
9
dtc humoral
8
response srbc
8
single cyclophosphamide
8
cyclophosphamide dose
8
dtc mg/kg
8
non-immunized mice
8
mice treated
8

Similar Publications

Human cytomegalovirus (HCMV) encodes four viral Fc-gamma receptors (vFcγRs) that counteract antibody-mediated activation in vitro, but their role in infection and pathogenesis is unknown. To examine their in vivo function in an animal model evolutionarily closely related to humans, we identified and characterized Rh05, Rh152/151 and Rh173 as the complete set of vFcγRs encoded by rhesus CMV (RhCMV). Each one of these proteins displays functional similarities to their prospective HCMV orthologs with respect to antagonizing host FcγR activation in vitro.

View Article and Find Full Text PDF

Feline herpesvirus 1 (FHV-1) is an important pathogen causing infectious rhinotracheitis in felids, mainly infecting the upper respiratory tract and conjunctiva. Multiple vaccines are available to prevent FHV-1 infection, and the antibody levels are always used to evaluate their effectiveness. However, the cellular immunity response following immunization in cats remains unclear.

View Article and Find Full Text PDF

Background: The rapid mutation of avian influenza virus (AIV) poses a significant threat to both the poultry industry and public health. Herein, we have successfully developed an mRNA-LNPs candidate vaccine for H5 subtype highly pathogenic avian influenza and evaluated its immunogenicity and protective efficacy.

Results: In experiments on BALB/c mice, the vaccine candidate elicited strong humoral and a certain cellular immune responses and protected mice from the heterologous AIV challenge.

View Article and Find Full Text PDF

We immunized three groups of Mojave desert tortoises (Gopherus agassizii): a group immunized twice, a group immunized once, and a group sham-immunized. We used the antigen, ovalbumin (OVA), with Freund's adjuvant to elicit antibody responses similar to those induced by extracellular bacteria. All tortoises have relatively high levels of B1 lymphocytes and natural antibodies (NAbs), and the goal of this study was to quantify B2 lymphocyte activity (antibody production and potential proliferation) that occurs in primary and secondary immunizations against this constitutive, first line of humoral defense.

View Article and Find Full Text PDF

Background: Given the limited available data about to the number of vaccine doses administered over an extended time in Iran, the immune status of vaccinated individuals and any potential disparities in this regard among those who received different numbers of vaccine doses remain unknown. Therefore, this study aimed to assess humoral immunity of individuals who received different doses of the COVID-19 vaccines in Iran.

Methods: This study was conducted from February, 2022 to December 2023 including 605 vaccinated subjects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!